34 / 64
1ª línea: estudios en marcha
CLEAR
Combination VEGFR + mTOR/PD-1 inhibition
Phase III
S iti ib un n
50 mg/day 4/2
R
n=735
Lenvatinib + pembro
20 mg/day + 200 mg (IV) every 3
weeks
Lenvatinib + everolimus
Primary endpoint: PFS
18 mg/day + 5 mg/day
https://clinicaltrials.gov/ct2/show/NCT02811861; Motzer RJ, et al. Lancet Oncol 2016; Taylor MH, et al. ESMO 2016